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OBJECTIVES: To explore the risk of uncontrolled chemotherapy-induced nausea and 
vomiting (CINV) associated with palonosetron (a 5-hydroxy tryptamine3-receptor 
antagonist [5-HT3-RA]) initiation versus other 5-HT3-RAs among patients with cancer 
on chemotherapy (CT) treatment in a hospital outpatient setting. METHODS: Patients 
with a cancer diagnosis initiating CT and anti-emetic prophylaxis with palonosetron 
(Group 1) and other 5-HT3-RAs (Group 2) for the ﬁ rst time (index date) between 
April 1, 2007 and March 31, 2009 were identiﬁ ed from the Premier Perspective (TM) 
Database. Inclusion criteria were patients aged ≥18 years, no evidence of nausea and 
vomiting or a hospital charge for a CT or anti-emetic medication in the 6-month 
pre-index date period, and 36 consecutive months of hospital data submission. 
Patients were followed through eight CT cycles or 6 months post-index date, which-
ever occurred ﬁ rst. a negative binomial distribution-generalized linear multivariate 
regression model estimating the number of CINV events on CT-matched groups in 
the follow-up period was developed after adjusting for several demographic and clini-
cal variables. RESULTS: Of 9144 identiﬁ ed patients, 1775 initiated palonosetron 
(Group 1; 19.4%). Group 1 patients were signiﬁ cantly younger (61.2 [SD: 13.0] vs. 
62.8 [13.1] years; P < 0.0001), comprised more females (52.5% vs. 41.1%; P < 
0.0001), less Blacks (8.6% vs. 13.2%; P < 0.0001), more highly emetogenic CT 
(43.3% vs. 28.5%; P < 0.0001), and more lung (26.1% vs. 22.4%; P < 0.0001) and 
breast cancer patients (19.3% vs. 15.3%; P < 0.0001). In the follow-up period, the 
number of unadjusted CINV events was statistically lower for Group 1 (8336 vs. 9400; 
P = 0.0007) patients. The regression model predicted a 13.7% decrease in the total 
CINV events per patient per cycle for Group 1 patients versus Group 2 patients; P = 
0.0006. CONCLUSIONS: In this retrospective hospital outpatient study, patients with 
cancer initiated on palonosetron were more likely to experience a signiﬁ cantly lower 
rate of CINV events versus those initiating other 5-HT3-RAs.
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OBJECTIVES: To characterize the changes in chemotherapy-induced nausea and 
vomiting (CINV) events by chemotherapy (CT) emetogenicity among patients with 
cancer initiating CT treatment in a hospital outpatient setting. METHODS: Patients 
with cancer initiating CT for the ﬁ rst time (index date) between April 1, 2007 and 
March 31, 2009 were extracted from the Premier Perspective comparative database. 
Patients aged ≥18 years, no evidence of nausea and vomiting or a hospital charge for 
a CT agent or antiemetic medication in the 6-month pre-index period, and 36 consecu-
tive months of hospital data submission were included. Patients were followed through 
eight CT cycles or 6 months post-index date, whichever occurred ﬁ rst. CT was catego-
rized as highly emetogenic (HEC), moderately emetogenic (MEC), low emetogenic 
(LEC), or minimal emetogenic (MinEC) per National Comprehensive Cancer Network 
guidelines. a descriptive analysis of changes in CINV events (either a diagnosis of 
nausea and/or vomiting or evidence of CINV-related medications) per CT cycle per 
CT emetogenicity was performed in the follow-up period. RESULTS: The overall 
study population (N = 11,495) had an average age of 63.3 years (SD 13.4), was 50.7% 
female, and 86% white. Most common tumor types were lung (19.8%), breast 
(15.9%), and urinary tract (13.8%). Use of HEC (cycle 1: 26.0% vs. study end: 9.8%; 
P = < 0.0001) decreased over the follow-up period. Change in CINV events from cycle 
1 to study end was statistically signiﬁ cant for HEC (32.1% vs. 29.9%; P < 0.0001), 
MEC (38.4% vs. 39.9%; P < 0.0001), LEC (26.4% vs. 27.8%; P < 0.0001), and 
MinEC (3.2% vs. 2.4%; P < 0.0001). The % point change from cycle 1 to study end 
was also statistically signiﬁ cant between groups (HEC [−2.2%] vs. MEC [+1.5%] vs. 
LEC [+1.4%] vs. MinEC [−0.8%]; P < 0.0001). CONCLUSIONS: In this retrospective 
hospital outpatient study, patients with cancer initiated on MEC and LEC experienced 
signiﬁ cantly higher CINV events over time versus HEC-initiated patients.
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OBJECTIVES: CINV with MEC and HEC therapy is well studied, but the association 
of prior history of CINV with the future risk of CINV is not well quantiﬁ ed. This 
study assessed the increased likelihood of a subsequent CINV following a ﬁ rst admin-
istration CINV in patients on single-day MEC/HEC therapy. METHODS: A retro-
spective analysis was conducted utilizing Georgia Cancer Specialists electronic medical 
records database (October 2006–August 2009). Patients who received >1 single-day 
MEC/HEC administration with no chemotherapy 3 months prior were included. 
Patients who received multiday chemotherapy, started with low emetogenic chemo-
therapy, or had no dosing information were excluded. Two cohorts, a ﬁ rst administra-
tion CINV (Group 1) and no ﬁ rst administration CINV (Group 2), were created and 
followed for 6 months. a multivariate logistic regression assessed the likelihood of 
subsequent CINV during the 6-month follow-up, controlling for age, gender, Charlson 
comorbidity index, cancer type, gap between administrations, and chemotherapy 
emetogenicity. Sub-analyses were performed for patients initiated on MEC and HEC. 
RESULTS: A total of 3721 patients met inclusion criteria; 423 (11.37%) experienced 
a ﬁ rst administration CINV. These patients were younger (56.6 vs. 59.4; P < 0.0001), 
had lower comorbidity index (2.1 vs. 2.2; P = 0.0154), and had more gaps between 
administrations (18.5 vs. 17.4; P = 0.0204). Unadjusted subsequent CINV rate was 
higher in the Group 1 cohort (52.3% vs. 24.2%; P < 0.0001). After controlling for 
covariates, Group 1 patients were 3.5 times more likely to have a subsequent CINV 
compared to Group 2 patients (odds ratio [OR]: 3.48 [95% CI: 2.81–4.30]; P < 
0.0001). Sub-analyses by MEC/HEC supported overall analysis (HEC OR: 2.9 [95% 
CI: 2.1–3.9; P < 0.0001]) and (MEC OR: 4.1 [95% CI: 3.1–5.5; P < 0.0001]). CON-
CLUSIONS: In this retrospective analysis, patients receiving single-day MEC/HEC 
who had a prior CINV were at increased risk of subsequent CINV. Further research 
on the clinical and economic impact of early and appropriate anti-emetic prophylaxis 
is required.
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OBJECTIVES: To perform an update of the previously published systematic review 
and meta-analysis (Engel T. et al. ISPOR 2009) of all randomized controlled trials 
comparing a single intravenous dose of PAL 0.25 mg with other 5-HT3R in patients 
receiving MoHE chemotherapy. METHODS: Several databases were searched, including 
MEDLINE, EMBASE, LILACS, and CENTRAL. The primary end points were the inci-
dence of acute and delayed nausea and vomiting. The adverse events of each treatment 
were analyzed. a subgroup analysis was performed to evaluate the impact of the use of 
concomitant corticosteroids. The results are expressed as risk ratio (RR) and the corre-
spondent 95% conﬁ dence interval (CI). RESULTS: Six studies were included, compris-
ing 2201 patients. PAL was compared to Ondansetron, Granisetron, and Dolasetron. 
Patients in PAL group had less nausea, both acute (RR = 0.86; CI 95% = 0.76 to 0.96; 
P = 0.007) and delayed (RR = 0.82; CI 95% = 0.75 to 0.89; P < 0.00001). They also 
had less acute vomiting (RR = 0.77; CI 95% = 0.67 to 0.88; P = 0.0001) and delayed 
vomiting (RR = 0.78; CI 95% = 0.70 to 0.86; P < 0.00001). There were no statistical 
differences in adverse events like headache (RR = 0.84; CI 95% = 0.61 to 1.17; P = 
0.30), dizziness (RR = 0.40; CI 95% = 0.13 to 1.27; P = 0.12), constipation (RR = 
1.29; CI 95% = 0.77 to 2.17; P = 0.33), or diarrhea (RR = 0.67; CI 95% = 0.24 to 
1.85; P = 0.44). Patients receiving PAL presented less nausea and vomiting regardless 
of the use of corticosteroids. CONCLUSIONS: PAL was more effective than the other 
5-HT3R in preventing acute and delayed CINV in patients receiving MoHE treatments, 
regardless of the use of concomitant corticosteroids.
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OBJECTIVES: Doxorubicin is an anthracycline used in the treatment of breast cancer, 
but its use is limited by cumulative dose-dependent cardiotoxicity. Pegylated liposomal 
doxorubicin is a novel drug delivery system that alters biodistribution of doxorubicin 
resulting in reduced cardiotoxicity. Our aim is to compare the efﬁ cacy and cardiotoxic-
ity of pegylated liposomal doxorubicin and conventional doxorubicin in ﬁ rst-line 
treatment of metastatic breast cancer (MBC). METHODS: The literature databases 
(Cochrane Library, EMBASE, and PUBMED) were searched from inception to May 
2010. Randomized controlled trials assessing the efﬁ cacy and cardiotoxicity of 
pegylated liposomal doxorubicin compared to conventional doxorubicin in ﬁ rst-line 
treatment of MBC were included. Two reviewers independently selected trials, assessed 
quality, and extracted data, and a third reviewer resolved discrepancies. The ﬁ xed 
effects meta-analysis was performed in STATA 9.0 using a standard meta-analysis 
approach. RESULTS: Two studies assessing pegylated liposomal doxorubicin with 
conventional doxorubicin for ﬁ rst-line treatment of MBC met the study criteria. 
Overall survival (HR = 0.869 [95% CI; 0.720, 1.049]) and overall response rate (RR 
= 0.908 [95% CI; 0.725, 1.139]) were comparable between the two arms. Treatment 
with pegylated liposomal doxorubicin resulted in signiﬁ cant reduction in cardiotoxic-
ity as compared to conventional doxorubicin (RR = 0.312 [95% CI; 0.198, 0.490]). 
The results of random effect analysis were similar (data not shown). CONCLUSIONS: 
Pegylated liposomal doxorubicin provides comparable antitumor activity in terms of 
efﬁ cacy and is better tolerated as compared to conventional doxorubicin in the treat-
ment of MBC. Thus, the liposomal drug delivery system can play a signiﬁ cant role in 
the use of doxorubicin in MBC treatment which is otherwise limited by its cardiotoxic-
ity and supports its use in ﬁ rst-line treatment of MBC.
